课题基金 / 基金详情

GENDER DIFFERENCES IN DRUG METABOLISM--A PILOT STUDY

GENDER DIFFERENCES IN DRUG METABOLISM--A PILOT STUDY
药物代谢的性别差异——一项试点研究
批准号:
6275196
负责人:
CELESTE M LINDLEY
金额:
$1.58万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

CELESTE M LINDLEY的其他基金

相似基金

相关文献

中文摘要
翻译
这项初步研究将评估性别和外源性的影响 激素对男性和女性肝脏细胞色素P450 3A4活性的影响这个 主要目的是比较受试者体内的平均系数 变异(C.V.)尿6-B-羟基皮质醇/皮质醇比值 (6-B-)H-皮质醇:皮质醇),在四周内测定, 三个研究组:未接受外源性激素的妇女,妇女 接受Triphasil,和男人。次要目标包括使用 第二个代谢探针,右美沙芬,雌激素和孕酮 以进一步评估这些性别差异。
英文摘要
This pilot study will assess the effects of gender and exogenous hormones on hepatic cytochrome P450 3A4 activity in men and women. The primary objective is to compare the mean intrasubject coefficient of variation (C.V.) of the ratio of urinary 6-B-hydroxycortisol to cortisol (6-B-)H-cortisol:cortisol), determined over a four week period, among the three study groups: women not receiving exogenous hormones, women receiving Triphasil, and men. Secondary objectives include use of a second metabolic probe, dextromethorphan, and estrogen and progesterone concentrations to further assess these gender differences.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CYP2B6 GENOTYPE-PHENOTYPE AND THE INFLUENCE OF SEX AND ETHNICITY
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA
EVALUATING THE EFFECT OF APREPITANT ON CYCLOPHOSPHAMIDE PHARMACOKINETICS
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA
海外基金